Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

(2012) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

(2012) C. Leonardi et al.   BRITISH JOURNAL OF DERMATOLOGY

Implementing treatment goals for successful long-term management of psoriasis

(2012) U. Mrowietz   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice

(2010) M. Blom et al.   ARTHRITIS CARE & RESEARCH

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

Etanercept combined with methotrexate for high-need psoriasis

(2008) R.J.B. Driessen et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY